Research Information System
TBS INTERNATIONAL BIOCHEMISTRY CONGRESS 2022, İzmir, Turkey, 26 - 30 October 2022, vol.50, pp.46, (Summary Text)
BACKGROUND AND AIM: This study aims to define a molecular
marker and a new epigenetic treatment target that can predict
treatment response and prolong survival by determining the relationship
between the expression and promoter region methylation of
the OGG1 (8-Oxoguanine DNA Glycosylase 1) gene, which is involved
in DNA repair in pancreatic tumors, with the survival time
of patients.
MATERIALS and METHODS: In the study, tumor tissue samples
from 50 patients with pancreatic adenocarcinoma and normal tissue
samples adjacent to the tumor were used. Total DNA was isolated
from formalin-fixed paraffin tissue sections with the kit. OGG1
promoter methylation was determined by methylation-specific polymerase
chain reaction after bisulfite modification in isolated DNA
samples. OGG1 expression in tumor and normal pancreatic tissues
was determined by immunohistochemical staining.
RESULTS: DNA repair gene OGG1 promoter methylation was
found to be higher in pancreatic tumor tissue compared to normal
pancreatic tissue. No significant difference was found when OGG1
immunopositivity in tumor and normal pancreatic tissue was compared.
When the data were evaluated according to gender, no statistically
significant difference was found between the OGG1 promoter
methylation levels in tumor and normal pancreatic tissues in
women, while OGG1 promoter methylation was found to be higher
in tumor tissue compared to normal tissue in men. When survival
was compared with OGG1 methylation levels and expression, no
statistically significant difference was found.
CONCLUSION: OGG1 promoter methylation is increased in tumor
tissue of patients with pancreatic adenocarcinoma. However,
the increased promoter OGG1 methylation in these patients was
not associated with OGG1 expression and survival.
Keywords: pancreatic cancer, ogg1, methylation, survival